Our data also showed that administering NVP-BEZ235 both in vivo and in vitro could abrogate the phosphorylation of AKT, GSK3β, S6K and 4E-BP1 via dually inhibiting PI3K and mTOR kinase in NPC, harbouring activating mutations of PI3K/AKT pathway. This evidence concerns the gene AKT1 and nasopharyngeal carcinoma.